Correction: Cardiovascular Diabetology (2024) 23:57 https://doi.org/10.1186/s12933-024-02150-0
Following publication of the original article [1], the authors noticed an error in the hazard ratio (HR) for the hospitalization for heart failure (HHF) outcome in the abstract. The numbers in the other parts of the manuscript and the tables were correct.
In abstract section, the correct sentence should read “Compared with GLP-1RA, empagliflozin was associated with similar risks of MI or stroke [HR: 0.99 (0.92, 1.07); RD: − 0.23 (− 1.25, 0.79)], and lower risks of HHF [HR: 0.69 (0.62, 0.77); RD: − 2.28 (− 2.98, − 1.59)], MACE [HR: 0.90 (0.82, 0.99); RD: − 2.54 (− 4.76, − 0.32)], cardiovascular mortality or HHF [HR: 0.77 (0.69, 0.86); RD: − 4.11 (− 5.95, − 2.29)], and ESKD [0.75 (0.60, 0.94); RD: − 6.77 (− 11.97, − 1.61)].”
Figure 3 was also cut off on the right side with some columns missing which has now been corrected (Fig. 3).
Subgroup analyses for primary outcomes by age and sex. CAPTION: On the relative scale, empagliflozin was associated with a lower risk of MI/stroke in patients 65 years or older, while it was not associated with MI/stroke in patients younger than 65 years. The HR estimates were consistent across other subgroups for all outcomes. For all outcomes, RD estimates were larger in older than in younger patients, while they did not differ by sex
Reference
Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Schmedt N, Koeneman L, Déruaz-Luyet A, Paik JM, Patorno E. Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study. Cardiovasc Diabetol. 2024;23(1):57. https://doi.org/10.1186/s12933-024-02150-0.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Htoo, P.T., Tesfaye, H., Schneeweiss, S. et al. Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study. Cardiovasc Diabetol 23, 103 (2024). https://doi.org/10.1186/s12933-024-02190-6
Published:
DOI: https://doi.org/10.1186/s12933-024-02190-6